First Monoclonal Antibody Trial Launched in COVID-19 Patients


Senior Member
East Coast USA
Eli Lilly has launched a Phase 1 trial of monoclonal antibody LY-CoV555 giving varying doses to 32 patients at NYU Medical School in New York, Cedars-Sinai in Los Angeles, and other centers across the country.

Goals are to assess side effects and tolerability of this investigational drug with results due by the end of June.

If successful, Phase 2 will involve larger numbers of volunteers to determine if it is an effective treatment and whether it can prevent COVID-19 in vulnerable groups.

Lilly has begun manufacturing LY-CoV555 in bulk anticipating success and in response to the urgent need for a COVID-19 treatment. The goal is to have hundreds of thousands of doses available by the end of the year.